ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma

A Correa;O Jegede;H Haas;K Flaherty;M Pins;A Andeniran;E Messing;J Manola;C Wood;C Kane;M Jewett;J Dutcher;R DiPaola;M Carducci;R Uzzo European Urology Jul;80(1):20-31. doi: 10.1016/j.eururo.2021.02.025. Epub 2021 Mar 9.

PMid: PMID33707112

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial

Z Lee;O Jegede;N Haas;M Pins;E Messing;J Manola;C Wood;C Kane;M Jewett;K Flaherty;J Dutcher;R DiPaola;R Uzzo Journal of Urology Apr;203(4):684-689

PMid: PMID31596672 | PMC number: PMC7337326

An Anatomic Classification System for Local Recurrence Following Resection of Intermediate and High Risk Non-Metastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Trial

Z Lee;O Jegede;N Haas;M Pins;E Messing;J Manola;C Wood;C Kane;M Jewett;K Flaherty;J Dutcher;R DiPaola;R Uzzo Journal of Urology Vol. 201, No. 4S, Supplement, abst MP14-18, poster (American Urological Association Annual Meeting,May 3-6, 2019, Chicago, IL)

Retroperitoneal lymphadenectomy in high-risk non-metastatic renal cell carcinoma: an analysis of the ASSURE (ECOG 2805) Adjuvant Trial

B Ristau;J Manola;N Haas;DY Heng;E Messing;CG Wood;C Kane;R DiPaola;R Uzzoa Journal of Urology Jan;199(1):53-59; Jul 17 [Epub ahead of print]

PMid: PMID28728992 | PMC number: PMC5800986

Adjuvant therapy for high-risk kidney cancer: ECOG-ACRIN E2805

NB Haas;J Manola;R Uzzo;K Flaherty;C Wood;C Kane;M Jewett;J Dutcher;MB Atkins;M Pins;G Wilding;D Cella;L Wagner;S Matin;T Kuzel;W Sexton;Y Wong;T Choueiri;R Pili;R Puzanov;M Kohli;W Stadler;M Carducci;R Coomes;R Dipaola Lancet May 14;387(10032):2008-2016; 2016 Mar 8 [Epub ahead of print]

PMid: PMID26969090 | PMC number: PMC4878938

Results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial

NS Balzer-Haas;J Manola;RG Uzzo;MB Atkins;G Wilding;M Pins;M Jewett;D Cella;C Kane;L Wagner;R Coomes;C Wood;J Dutcher;KT Flaherty;R DiPaola Journal of Clinical Oncology 33 (suppl 7; abstr 403); ASCO GU Cancers Symposium (February 26-28, 2015, Orlando, FL), general poster session;

Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805

N Haas;B Ky;K Flaherty;R Uzzo;CJ Kane;MAS Jewett;L Wood;CG Wood;MB Atkins;JJ Dutcher;G Wilding;RS DiPaola Clinical Cancer Research 21(18):4048-4054

PMid: PMID25967143 | PMC number: PMC4573791

Lymphadenectomy at the time of surgery for high risk localized RCC: results from the ASSURE adjuvant trial (ECOG 2805)

R Uzzo;J Manola;N Haas;C Kane;C Wood;M Jewett;R DiPaola Journal of Urology Vol. 191, No. 4S, Suppl., p. e283 (PD10-04); poster; American Urological Assn Annual Meeting (May 16 -21, 2014, Orlando, FL);

Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC)

N Haas;J Manola;B Ky;KT Flaherty;RG Uzzo;CG Wood;CJ Kane;MAS Jewett;MB Atkins;JP Dutcher;RS DiPaola Journal of Clinical Oncology 30(suppl; abstr 4500); oral; ASCO Annual Meeting (June 1-5, 2012, Chicago, IL)